Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

ZUG, Switzerland - Friday, 05. December 2025

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1

Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour

Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs

The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs

 

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body.

Meeting the moment: evolving patient needs

As aesthetic expectations shift, patients are seeking more holistic treatment approaches that address the body as well as the face. Nine out of ten women report aesthetic concerns beyond the face, including skin laxity, volume loss, and cellulite.6 The gluteal silhouette, in particular, is a focal point of beauty and confidence, with growing demand for non-surgical treatments that enhance its shape and definition.7 Sculptra’s regenerative effects on collagen and elastin as well as its ability to restore skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour make it uniquely suited to meet these evolving needs.1-5,8-12

 

“Sculptra’s new and expanded indications mark an important evolution in how we approach aesthetic medicine – moving from facial rejuvenation to full-body restoration. With its proven ability to improve firmness, volume, and skin quality beyond the face, this certification empowers us to treat our patients more holistically, combining science, artistry, and confidence in a truly individualized way.”

 

FLAVIA RADKE, M.D.

PLASTIC SURGEON

VITA AESTHETICA, GERMANY

 

 

In studies focused on areas such as the gluteal area, posterior thighs, décolletage, and upper arms, patients treated with Sculptra experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour.2-5 Improvements were visible as early as one month after treatment and studies showed that:

In the buttocks, 84% of patients were rated as having “improved” or more by physicians using the Global Assessment of Improvement Scale at six months and 96% reported high satisfaction3

In the thighs, visible improvements were seen as early as one month after treatment, and, at one year, 100% of patients noted visual improvements, and 93% reported reduced sagginess, with 97% of patients expressing they were satisfied with the appearance of their thighs and 83% indicating they would choose to do it again4

In the décolletage, 13% of patients saw a reduction in wrinkling at Month 1 and wrinkle severity visibly decreased in 93% of patients by Month 9. More than 80% of patients were satisfied with the improved quality (including texture and firmness) of their skin2

In the upper arms, visible improvement in skin firmness and quality was seen just two months after a three-session treatment and patients were satisfied with the treatment5

 

“The certification of Sculptra for body indications in the EU marks an exciting evolution in injectable aesthetics. With these new body indications extending Sculptra's trusted profile beyond the face, we are empowering practitioners to deliver natural-looking, long-lasting results across broader treatment areas, reinforcing Galderma’s commitment to innovation and holistic patient care.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

 

 

The broadest aesthetics portfolio backed by science, reinforcing Galderma’s commitment to continuous innovation and regulatory excellence

The EU MDR certification is part of Galderma’s broader MDR transition strategy, which encompasses its full portfolio of aesthetic injectables, such as its Restylane® hyaluronic acid injectables, and dermatological devices. It confirms that Sculptra meets the highest standards of safety, performance, and quality under the updated regulatory framework. While this milestone supports Sculptra’s certification for body indications, it also reinforces Galderma’s broader commitment to delivering innovative, safe and science-backed solutions across its aesthetics portfolio.

First approved in the EU in 1999, Sculptra pioneered a new approach to volume restoration by stimulating the body’s own collagen production.1,13,14 Over the past 25 years, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, making it the first proven regenerative biostimulator. With its expanded indication, Sculptra brings its trusted efficacy to the body, offering patients and practitioners a new opportunity to achieve holistic, full-body aesthetic care.

This material refers only to the product certified under Regulation (EU) 2017/745 (MDR). Legacy versions of the product remain available. For full product information and the Instructions for Use (IFU), visit: https://www.galderma.com/sites/default/files/2025-12/IFU_Sculptra_MDR.pdf

About Sculptra

Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide, progressive, and sustained regenerative effect across all three skin layers.1,10-16 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.1,10,11,17-19 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.1-5,10,11,20 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.1,4,9,15,20

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Sculptra®. EU Instructions for Use. 2025. Available online. Accessed December 2025.

Galderma. Data on File (MA-57540).

Nikolis A, et al. A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-Lactic Acid for the Treatment of Contour Deformities of the Buttock Regions. J Drugs Dermatol. 2022;21(3):295–303.

Beleznay K, et al. Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study. Poster presented at the IMCAS World Congress; February 1-3, 2024; Paris, France.

Mazzuco R, et al. Clinical and Histological comparative outcomes after injections of Poly-L-Lactic Acid and Calcium Hydroxyapatite in arms – a split side study. J Cosmet Dermatol. 2022;21(12): 6727–6733.

IFOP for NSH - Skin Quality Concerns - September 2019.

De la Peña JA, et al. History of gluteal augmentation. Clin Plast Surg. 2006 Jul;33(3):307-19.

Galderma. Date on File (MA-60875).

Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915–922.

Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.

Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024; October 17-20, 2024; Orlando, Florida, United States.

Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285–288.

Galderma. Data on File (MA-46589).

Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.

Widgegrow J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds). Poster presented at IMCAS World Congress; February 1-3, 2024. Paris, France.

Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474).

Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transplant. 2018;27(5):729–738.

Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43.

Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108.

Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at IMCAS World Congress; January 26-28, 2023; Paris, France.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204988559/en/

Permalink

https://www.aetoswire.com/en/news/0512202551499

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds

 79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration

40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns

92% of LPs say specialist outsourcing enhances transparency

 

(BUSINESS WIRE) -- Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals.

Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1

While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sharply when it comes to operational readiness. Nearly eight in 10 GPs (79%) anticipate growth in the sector over the next three years, with more than half (51%) expecting a significant acceleration. LPs, however, are increasingly cautious—40% reported turning down multiple fund or investment opportunities last year due to operational concerns such as inconsistent reporting standards and unclear risk frameworks.

“The global expansion of private credit is undeniable, but the operational complexity it brings must not be underestimated,” said Bas Coenen, CSC’s head of Fund Solutions, Europe. “Operating across multiple jurisdictions introduces a maze of reporting requirements, investor expectations, and compliance standards. Even managing a handful of markets can prove challenging. The message from investors is clear: confidence in cross-border strategies hinges on transparency, regulatory alignment, and flawless execution.”

GPs recognize the operational challenges that come with cross-border expansion—particularly around anti-money laundering (AML) regulations, multijurisdictional reporting, and enforcing covenants across diverse legal systems. Transparency and reporting demands from LPs now rank among managers’ top concerns, second only to the complexity of deal structuring.

At the same time, LPs are shifting their priorities toward more granular and consistent data on loan performance and borrower credit quality. These metrics now rank just behind loan-level returns and borrower payment trends, while broader measures such as liquidity and portfolio risk visibility are being assessed through this more granular data.

To meet rising expectations and scale effectively, many GPs are investing in technology upgrades and partnering with specialist service providers. Currently, 82% rely on third-party loan agents, with 66% doing so regularly over the past year, and 88% expect usage to increase. LPs strongly endorse this shift: 92% believe GPs who outsource to trusted specialists are better equipped to deliver enhanced reporting and risk transparency, especially in complex cross-border environments.

“Private credit is inherently a hands-on asset class - far more operationally intensive than equity investing,” said CSC’s David Kim, managing director, North America. “LPs know the data is available, and they’re demanding more of it—greater transparency, consistency, and detail. That’s putting real pressure on managers to elevate their reporting capabilities and strengthen operational frameworks.”

He added: “Many are now seeking partners who can support them across the full investment life cycle, from loan agency and fund administration to SPV management. CSC is among the few with the scale, expertise, and infrastructure to deliver truly end-to-end solutions.”

To receive a copy of CSC’s Private Credit 2025: Global Strategies for a $1.5 Trillion Market, please download it at cscglobal.com/service/campaigns/private-credit-2025.

1CSC, in partnership with PureProfile, surveyed 500 private capital professionals globally, comprising 300 GPs and 200 LPs across North America, Europe (including the U.K.), and Asia-Pacific. Respondents held senior positions within fund management, investment, and risk functions across asset management, pension funds, insurance, and wealth management sectors.

About CSC

CSC is the leading provider of business administration and compliance solutions, offering industry-leading expertise and unmatched global reach to alternative fund managers and capital markets participants. Leveraging deep institutional experience and a tailored approach, CSC delivers a comprehensive suite of fund administration, trust, agency, and compliance services to support a wide range of private and public market transactions, complex fund strategies, and scalable operations.

As the trusted partner of choice for more than 70% of the PEI 300 and 90% of the Fortune 500®, CSC helps clients navigate operational and transactional complexities across more than 140 jurisdictions and various asset classes. With extensive worldwide capabilities, our expert teams provide solutions tailored to each client’s needs. Privately held and professionally managed since 1899, we combine global reach, local expertise, and innovative solutions to help our clients succeed.

We are the business behind business®. Learn more at cscglobal.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204982051/en/

Permalink

https://www.aetoswire.com/en/news/0412202551460

Contacts

For more information:

Citigate Dewe Rogerson

Hassan Ali / Thomas Dalton

cscteam@cdrconsultancy.com

CSC

Katie Scott-Kurti

Head of Brand and Communications

katie.scottkurti@cscglobal.com

CSC News Room

 

Arabian Ethicals Partners with Accord Healthcare to Advance Patient Access Across the UAE

 

 Dubai, United Arab Emirates - Thursday, 04. December 2025

Strategic Collaboration to Expand Availability of Essential Cancer Therapies and Oncology Treatments Across the UAE

Arabian Ethicals, a Ghobash Group enterprise with a 48-year legacy of advancing the UAE’s healthcare ecosystem, and Accord Healthcare, one of Europe's fastest-growing pharmaceutical companies, headquartered in the United Kingdom, are pleased to announce a strategic partnership aimed at enhancing the availability and accessibility of essential cancer therapies and critical oncology treatments for patients across the UAE.

Strengthening Access to High-Quality, Life-Saving Treatments

This partnership marks an important milestone in strengthening patient access to high-quality treatments in the UAE. Arabian Ethicals, with its long-standing role in the UAE healthcare supply chain, continues to support hospitals, clinics, and pharmacies in both public and private sectors with reliable access to trusted pharmaceutical, medical, and wellness brands. The collaboration with Accord Healthcare aligns with Arabian Ethicals’ growth strategy of widening access to essential treatments, improving service standards, and reinforcing its position as a trusted healthcare partner in the UAE.

Commitment to Better Patient Care and Service Excellence

Ebru Yavuz, General Manager of Arabian Ethicals, said: “This partnership reflects our commitment to widening access to essential treatments and consistently raising service standards across the UAE. Arabian Ethicals has long supported healthcare providers nationwide, and working with Accord Healthcare strengthens our ability to meet patient needs, particularly in critical areas such as oncology.”

By collaborating closely with leading global manufacturers, Arabian Ethicals remains committed to elevating healthcare delivery and ensuring consistent availability of high-quality, internationally approved products.

Expanding Access to Accord’s Robust Oncology Portfolio

The partnership combines Arabian Ethicals’ strong presence in the UAE and market-access capabilities with Accord Healthcare’s extensive global portfolio and proven manufacturing expertise, particularly in oncology, where Accord has deep heritage.

Accord’s portfolio includes 37 oncology-related treatments, including key chemotherapy products that support care for prevalent tumour types such as breast and prostate cancer, alongside hematological conditions and supportive oncology care.
Introducing New Innovations to the UAE

The collaboration enables the introduction of upcoming products from Accord’s global pipeline, including biosimilars and novel therapies. This innovation pipeline is reinforced by Accord’s ongoing investments, including Accord Biopharma, London, its research and development facility in the United Kingdom focused on biologics and vaccines.
Shared Mission to Improve Patient Outcomes Across MENA

Hany Mashaal, Commercial Director MENA at Accord Healthcare, commented:
“We are pleased to partner with Arabian Ethicals in expanding the availability of vital and affordable oncology and essential cancer therapies across the UAE. This collaboration supports our mission to ensure patients benefit from Accord’s global expertise in generics, biosimilars, and oncology, and to deliver meaningful solutions that address evolving healthcare needs.”
A Long-Term Partnership to Support Healthcare Providers

This collaboration marks the beginning of a broader effort by both organizations to expand treatment access and support healthcare providers with reliable, high-quality solutions. The partnership reinforces their shared commitment to improving patient outcomes across the UAE.

About Arabian Ethicals

Established in 1977, Arabian Ethicals – a Ghobash Group Enterprise – is a leading UAE-based healthcare distributor with a strong focus on pharmaceuticals, consumer health, and animal care. The company enables global partners to navigate the UAE market through regulatory expertise, strong public-private relationships, and deep regional insight. With a portfolio spanning high-impact therapeutic areas such as oncology and diabetes, Arabian Ethicals is committed to improving patient access and advancing healthcare outcomes across the region.

For more information, visit arabianethicals.ae or write to info@arabianethicals.ae. You can also follow Arabian Ethicals on LinkedIn.

About Accord Healthcare:

Headquartered in the United Kingdom, Accord Healthcare is one of the fastest-growing pharmaceutical companies in Europe. Accord has one of the largest market footprints of any European generic and biosimilars company, selling generic medicines in over 80 countries around the world.2 This global footprint enables Accord to deliver vital, affordable medicines to national health systems, supporting healthcare professionals to transform patient lives worldwide. The company is committed to investment in manufacturing abilities and is building a new R&D facility in the United Kingdom to focus on biologics and vaccines.

Permalink
https://www.aetoswire.com/en/news/ae4122025e

Contacts

Tony Hamad

Group Marketing Director

+971 4 5961800

University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health

 Funding from Baszucki Group fuels program for healthcare professionals to learn by doing.

 

(BUSINESS WIRE)--Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and research settings.

The effectiveness of ketogenic metabolic therapy across a range of serious mental illnesses, including schizophrenia, bipolar disorder and major depressive disorder, is supported by growing evidence including pilot trials from institutes such as Stanford University School of Medicine, University of Edinburgh, and Ohio State University. With its potential to act as a transdiagnostic tool, ketogenic metabolic therapy is rapidly emerging as a powerful treatment option.

However, a critical gap exists. There is a lack of infrastructure for ketogenic metabolic therapy treatment for the vast majority of people. “Working in this field, I have received a tremendous outpouring from the community looking for guidance, both from families seeking this treatment option but also from clinicians looking for training options,” said Dr. Kelly. “This study is designed to improve access to care. It moves beyond knowledge sharing, equipping providers with the practical skills and confidence to implement a medical ketogenic diet and provide a truly personalized, holistic treatment option for patients.”

The comprehensive two-part program is specifically designed to build competence and confidence. Clinician participants will receive in-depth education on the nutritional science, treatment protocols, and implementation challenges of this approach. Crucially, they will also gain first-hand experience by personally engaging with the diet and tracking changes in their mental health and metabolic markers such as daily ketone and glucose levels. “Education alone is not always enough to change behavior,” Dr. Kelly explains. “A practical experiential piece is required to build the competence and confidence that is required for effective implementation.”

The immediate demand for this training confirms its necessity. “We’ve been blown away by the enthusiasm. The program was fully enrolled in a short space of time. This shows that there really is an appetite for this type of program,” Dr. Kelly noted. The program includes 40 participants drawn from the broader population of clinical care workers, including psychologists, physicians, and social workers.

This program is part of a continued commitment by Baszucki Group to expand access to metabolic therapies for patients with serious mental illness by supporting key research and capacity building projects. “Our hope is that the information gathered from this model will be used to shape the future development and expansion of similar programs globally,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group.

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202200908/en/

Permalink

https://www.aetoswire.com/en/news/4122025514611

Contacts

Baszucki Group media contact: media@baszuckigroup.org

NTT DATA Announces Six New AI-Powered Cyber Defense Centers to Strengthen Cyber Resilience and Counter an Evolving Threat Landscape

 LONDON - Thursday, 04. December 2025

Four next-generation autonomous Cyber Defense Centers are now operational in India, with two additional centers planned in the UK in 2025 and the USA in 2026

Built with Agentic AI for SecOps, GenAI-driven threat orchestration and advanced automation that delivers up to 60% faster investigations and 90% fewer alerts

Adds capacity for 800+ security analysts to protect global clients 24x7 through unified, AI-driven detection and response

 

(BUSINESS WIRE) -- NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of four next-generation autonomous Cyber Defense Centers powered by AI technologies in Bengaluru, Hyderabad, Noida and Mumbai, with two additional centers set to open in Birmingham (UK) in Dec 2025 and Dallas (USA) by Jan 2026.

These purpose-built Cyber Defense Centers reinforce NTT DATA’s strategic focus on modernizing cybersecurity for the AI era. They represent a shift from traditional centralized security operations to a distributed, AI-driven, hyper-automated model that learns from past incidents and human expertise to automate, triage and prioritize alerts, accelerate investigations and incident response, contain threats faster and support regional data privacy and cybersecurity regulations.

According to Omdia, autonomous Security Operations Centers (SOCs) will become the industry standard within two years, positioning NTT DATA as a leading example of how the industry is evolving toward autonomous cyber resilience.

Next-generation technology meets global and local expertise

The next-generation Cyber Defense Centers combine human security experts and AI agents to defend against evolving cyber threats. AI agents autonomously triage, analyze and hunt potential incidents, reducing investigation time by up to 60%, enabling teams to contain threats earlier in the kill chain. By automating high-volume, repetitive tasks, these capabilities free security analysts to focus on higher-value work such as digital forensics, containment and recovery.

Each center is purpose-built with cutting-edge technology. Key features include:

Autonomous agent-based cyberdefense and AI-driven threat orchestration to accelerate detection and response cycles.

Real-time global threat intelligence and localized threat hunting tailored to each region’s unique threat landscape.

A comprehensive portfolio of offerings, including Managed Detection & Response (MDR), Incident Response, Threat Intelligence, Compliance & Regulatory Advisory and Cloud & OT Security Services.

Proactive identification of new and emerging threats, along with a clear view of cyber risks and recommendations for reducing them.

Significant risk reduction & operational efficiency improvements, including up to 90% alert reduction and 60% faster mean time to detect and respond.

Powered by industry-leading technology platforms that leverage NTT DATA’s strategic partnerships.

“Our clients’ innovation and growth are driven by rapid adoption of cloud and AI technologies that must be secured at speed and scale,” said Charlie Li, Head of Cloud and Security Services, NTT DATA, Inc. “Our expanding footprint of next-generation Cyber Defense Centers enables us to meet the rising demand for AI-powered cybersecurity services, defend against AI-enabled threats and help our clients advance their edge-to-cloud digital transformation journeys.”

Global network with local expertise

The four Cyber Defense Centers in Bengaluru, Hyderabad, Noida and Mumbai, expand NTT DATA’s global cybersecurity footprint across five continents, supported by more than 40 delivery centers and SOCs in over 50 countries.

Together, these centers enhance coverage for more than 1,200 global clients by combining regional expertise with agentic AI, advanced automation and next-generation technologies.

The centers provide 24x7 unified threat monitoring, detection, response and incident management and are fully integrated with NTT DATA’s SecOps global network, delivering AI-driven insights and threat intelligence through a single dashboard for identification, detection, protection and recovery.

Additional Cyber Defense Centers will launch in Birmingham (UK, Dec 2025) and Dallas (USA, Jan 2026) further strengthening regional capabilities across NTT DATA’s global network.

These “glocal” Cyber Defense Centers operate in collaboration with regional Computer Emergency Response Teams (CERTs), National Cyber Security Centers (NCSCs) and government agencies to help clients meet local data privacy and AI-regulation requirements.

“Today’s threat environment demands intelligent, adaptive defenses that combine global insight with local expertise to help organizations continuously reduce risks and build resilience,” said Sheetal Mehta, Head of Cybersecurity, NTT DATA, Inc. “With the addition of these AI-powered Cyber Defense Centers, we are advancing our vision of a globally interconnected cyberdefense network that combines cutting-edge technology, strategic partnerships and world-class talent.”

Benefits for clients

Next-generation AI-powered cyberdefense: As adversaries adopt AI and autonomous tactics, AI-enabled platforms help clients confidently address threats, navigate change confidently and build long-term digital trust.

Enhanced regional coverage with global intelligence: Global enterprises receive world-class unified detection and response services with local and global capabilities, bringing global threat intelligence closer to business operations and ensuring compliance with regional data privacy and regulatory requirements.

Expanded talent pool: Increased capacity of global and local cybersecurity professionals delivered through these new centers allows NTT DATA to scale human expertise alongside intelligent automation.

Secure digital transformation and growth: Clients can accelerate edge-to-cloud transformation while continuously protecting their expanding digital ecosystems.

More information can be found here Agentic AI for SecOps | NTT DATA.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D. Visit us at nttdata.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203998901/en/

Permalink

https://www.aetoswire.com/en/news/0412202551435

Contacts

Media Contact

Lori Bosio

lori.bosio@nttdata.com

Pace selected by Prudential Financial to help automate its insurance operations with agentic AI

  NEW YORK - Thursday, 04. December 2025 AETOSWire 

Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business

(BUSINESS WIRE)--Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery.

Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work.

“Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.”

This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operational efficiency.

“We’ve taken a step forward on our journey to modernize the customer acquisition process,” said Sara Atkinson, vice president of customer acquisition for Prudential’s ILI business. “With automated systems, our teams now have more time to focus on customer relationships, which supports Prudential’s broader goal of delivering industry-leading experiences for both clients and customers.”

ABOUT PACE

Pace is the agentic workforce for insurance. Pace’s AI agents navigate internal apps, reason across documents and make phone calls to automate tasks traditionally handled by business process outsourcers (BPOs). Pace works with leading insurers to handle mission-critical insurance operations like submission intake, policy servicing, claims handling and data entry. For more information, please visit withpace.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203008504/en/

Permalink

https://www.aetoswire.com/en/news/4122025514599

Contacts

Pace Media Contact

+1 (917) 791-0529

press@withpace.com

Pace Business Contact

Tristan Gosakti

tristan@withpace.com

 

Sharjah Concludes 54th Eid Al Etihad (Union Day) Celebrations with over 230,000 Visitors Across 250 Events

 

Sharjah, United Arab Emirates – 3 December 2025:

The Emirate of Sharjah concluded its 54th Eid Al Etihad (Union Day) celebrations yesterday, Tuesday. This event showcased the nation’s rich cultural heritage alongside a journey of development, innovation, community belonging, and coexistence, attracting citizens, residents, and visitors from around the world.

The celebrations spanned 14 days, from November 19 to December 2, and featured more than 250 activities that drew approximately more than 233 thousand participants across various cities and areas in the Emirate of Sharjah. This impressive turnout reflected the unique cultural character and identity of each region.

The events included spectacular marine and land parades, interactive educational workshops, and heritage exhibitions, alongside technology innovation corners showcasing robotic displays and smart experiences presented by Emirati youth. The celebrations also featured musical performances and traditional arts.

The celebrations highlighted the use of environmentally friendly materials and included educational workshops aimed at raising environmental awareness among children and youth. They also provided opportunities to explore traditional crafts and Emirati arts, effectively creating a bridge between authenticity and modernity. The programs focused on enhancing cultural interaction among citizens, residents, and visitors, making the Eid Al Etihad celebrations a rich experience that combines heritage, education, art, technology, community, and enjoyable interaction.

The 54th Eid Al Etihad (Union Day) celebrations saw broad participation from families, various segments of society, government departments, and cultural institutions. This edition became a global occasion reflecting the unity and cultural diversity of the UAE.

The celebrations projected a human-centered image that reinforces national identity, respects cultural diversity, promotes environmental sustainability, and embraces global openness to future-oriented ideas through the use of advanced technology. This edition of Eid Al Etihad became a global occasion reflecting the UAE’s unity, cultural diversity, and creativity, transforming the celebrations into a comprehensive community experience that enhances the value of unity and showcases the UAE’s distinctive values.

These celebrations reaffirmed Sharjah’s status as a global cultural hub that seamlessly blends heritage, art, technology, and education. They exemplified a pioneering model for tourism and international events, while delivering a global message that encourages cooperation among cultures and promotes innovation and creativity.

Source: AETOSWire

Contacts:
Mai Abdelmajeed
MAbdelmajeed@global-advisors.com

LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent

 MUMBAI, India & WARREN, N.J. - Thursday, 04. December 2025 AETOSWire Print 

 Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner

 

(BUSINESS WIRE)--LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality.

At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as:

The Industry Partner of the Year - Travel and Hospitality:

Recognized as a trusted transformation partner in Travel and Hospitality, LTIMindtree is enabling a global leader to modernize at scale—exiting global data centers and migrating seamlessly to AWS. The initiative has delivered accelerated modernization of critical business processes, such as billing, while markedly improving operational agility and performance. Additionally, retiring physical infrastructure has materially advanced the client’s sustainability goals by reducing the carbon footprint. Together, these outcomes are powering their digital-first vision and future-ready customer experiences.

The Application Modernization Consulting Partner of the Year:

As the strategic modernization partner to a leading U.S.-based insurer, LTIMindtree transformed core systems by migrating over 200 critical applications and complex mainframe workloads to AWS. This collaboration shifted IT from a traditional cost center to a value-driving enabler, accelerating innovation, product delivery, and revenue growth. Modernization enhanced underwriting through enhanced insights, improved policy issuance speed, and strengthened customer experience with highly reliable self-service and low-latency access to critical data. Together, these advancements have reinforced the client’s position as a technology-forward market leader.

“Being named AWS Partner of the Year in two categories highlights the strength of our collaboration with AWS and reflects the path-breaking work our teams deliver every day, helping enterprises modernize, innovate, and scale with confidence. Through our AI-driven approach and deep alignment with AWS, we empower clients with industry-specific solutions that unlock new possibilities and shape the next generation of transformation,” said Gururaj Deshpande, Chief Delivery Officer, LTIMindtree.

About LTIMindtree

LTIMindtree is a global technology consulting and digital solutions company that partners with enterprises across industries to reimagine business models, accelerate innovation, and drive AI-centric growth. Trusted by more than 700 clients worldwide, we use advanced technologies to enable operational excellence, elevated customer experiences, and long-term value creation. With a workforce of more than 86,000 talented and entrepreneurial professionals across over 40 countries, LTIMindtree — a Larsen & Toubro Group company — is dedicated to solving complex business challenges and delivering transformation at scale. For more information, please visit www.ltimindtree.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251201628111/en/

Permalink

https://www.aetoswire.com/en/news/4122025514566

Contacts

Media Contact: Gitanjali Sreepal, gitanjali.sreepal@ltimindtree.com

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

 ZUG, Switzerland -

‘BBB’ long-term issuer credit rating from S&P Global Ratings

Positive outlook, reflecting expected profitability improvement, ramp up of Nemluvio, and continued deleveraging and balance sheet improvement

Recognition of Galderma’s science-based dermatology portfolio and global operations

 

(BUSINESS WIRE) -- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook.

The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation.

S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow. The agency also notes Galderma’s disciplined financial policy, supporting expectations of continued deleveraging over the coming years.

The positive outlook indicates that an upgrade could be considered over the next 12–24 months subject to Galderma continuing to deliver profitable growth and maintaining credit-supportive metrics.

Galderma is also rated BBB (stable outlook) by Fitch.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203014636/en/

Permalink

https://www.aetoswire.com/en/news/0412202551437

Contacts

For further information:

Media

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Investors

Emil Ivanov

Head of Strategy, Investor Relations and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Rigaku Launches XTRAIA MF-3400, a Measuring Instrument for Next-generation Semiconductors

TOKYO - Thursday, 04. December 2025

High-precision wafer measurement meets surging demand from AI and data centers

 

(BUSINESS WIRE)--Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched the XTRAIA MF-3400, an instrument used in semiconductor manufacturing processes to measure the thickness and composition of wafers. The XTRAIA MF-3400 will significantly enhance productivity in the rapidly growing semiconductor market by enabling high-accuracy evaluation of materials essential for mass production of next-generation memory chips and high-speed AI devices.

As generative AI and data centers continue to expand, demand is rising for high-performance, energy-efficient semiconductors capable of processing vast volumes of data. Consequently, semiconductor structures are becoming more complex, delicate, and three-dimensional, with a single chip integrating billions of microscopic electronic components.

Stable mass production of these advanced devices requires nondestructive technologies capable of measuring and insulating metal films with nanoscale precision.

To meet this need, Rigaku further advanced the X-ray technologies it has cultivated over decades to develop the XTRAIA MF-3400. Among its new capabilities, the XTRAIA MF-3400 supports measurement of molybdenum, an element attracting attention as a next-generation material.

Key Features of the XTRAIA MF-3400

Measurement capability up to double that of previous devices

By doubling the X-ray dose and integrating a new transport system, the number of wafers measurable per hour is dramatically increased.

Nondestructive measurement with nanoscale accuracy

On a field as narrow as 50 µm, less than the width of a human hair, the XTRAIA MF-3400 can measure film thickness with sub-nanometer precision finer than the thickness of a single atom.

Multiple analyses on a single device

The XTRAIA MF-3400 incorporates three analytical functions using X-rays: fluorescent X-rays, X-ray reflectance, and X-ray diffraction. Measurement can be automated by registering optimal conditions in recipes, tailored to objectives including ultra-thin-film structure, thickness, or crystallinity.

Track Record and Prospects

KIOXIA Corporation and KIOXIA Iwate Corporation have decided to implement the XTRAIA MF-3400 into mass-production lines for 3D NAND flash memory1. The device is also expected to be used in next-generation memory production, where high capacity and high data transfer rates are essential and mass production adoption is imminent.

Moreover, manufacturers of DRAM2 and logic semiconductors3 are also expected to adopt the XTRAIA MF-3400. Combines with its predecessor model, Rigaku anticipates net sales to exceed JPY 6 billion in FY2026.

A range of modules can be selected for the XTRAIA MF-3400 tailored to different applications. This flexibility enables each manufacturer to construct the measurement environment that is ideal for its manufacturing processes. Leveraging these strengths in versatility and scalability, Rigaku will continue to develop applications in new material and process fields, aiming for sustainable growth of 20% per year in FY2027 and beyond for both model series.

1. Memory media that use a 3D structure to achieve high capacity, high speed and low power consumption

2. Volatile main-memory devices that hold data temporarily; high-speed operation is a key feature

3. Semiconductors used for processes such as calculation and control

Product Details

https://rigaku.com/products/semiconductor-metrology/xrr-edxrf-and-optical-tools/xtraia-mf-3400?setLang=english　

About the Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in 136 countries and regions and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”

For details, please visit: rigaku-holdings.com/english

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204537975/en/

Permalink

https://www.aetoswire.com/en/news/4122025514666

Contacts

Press Contact:

Sawa Himeno

Director, Communications Dept., Rigaku Holdings Corporation

prad@rigaku.co.jp